Skip to main content

Table 2 Eligibility criteria for outcomes

From: Viscoelastic testing for hepatic surgery: a systematic review with meta-analysis—a protocol

Outcome

Criteria

Data type

Planned summary measure

Primary outcome

1. 30-day mortality (all-cause)

Using mortality data in each eligible trial that is less than and closest to 30 days

Categorical

Relative risk

Secondary outcomes

1. Long-term mortality

Using mortality data in each eligible trial that is >30 days and the longest follow-up time for that trial

Categorical

Relative risk

2. Blood loss (mL)—included if measured from the start of surgery, defined a priori and measured equally in both groups. We will use follow-up that is closest to including 24 h after the end of surgery.

Numerical

Standardised mean difference

Number of participants receiving blood products—included if measured from the start of surgery, defined a priori and measured equally in both groups. We will use follow-up that is closest to including 24 h after the end of surgery.

Categorical

Relative risk

3. Any type of blood product

  

4. Autologous red blood cells

  

5. Any type of autologous coagulation factor

  

6. Autologous fresh frozen plasma

  

7. Autologous cryoprecipitate

  

8. Autologous platelets

  

Volume of blood products administered—included if measured from the start of surgery, defined a priori and measured equally in both groups. We will use follow-up that is closest to including 24 h after the end of surgery.

Numerical

Standardised mean difference

9. Red blood cells (mLs or units)

  

10. Fresh frozen plasma (mLs or units)

  

11. Cryoprecipitate (mLs or units)

  

12. Platelets (mLs or units)

  

Use of other pro-coagulant interventions—included if measured from the start of surgery, defined a priori and measured equally in both groups. We will use follow-up that is closest to including 24 h after the end of surgery.

Categorical

Relative risk

13. Tranexamic acid

  

14. Recombinant Factor VIIa

  

15. Other recombinant factor concentrates

  

16. Serious complications associated with blood loss and blood product transfusion—included if measured from the start of surgery, defined a priori and measured equally in both groups. We will use follow-up that is closest to including 24 h after the end of surgery.

- Unplanned intensive care unit (ICU) admission <24 h

- Myocardial infarction (MI) <7 days

- Cardiac arrest <24 h

- Central nervous system complications

 – Cerebrovascular accident (CVA) or traumatic brain injury (TBI) <7 days post-operation

- renal complications <7 days—where a clear definition of renal complications has been provided in the paper and measured equally in both groups

Categorical

Relative risk

17. Thromboembolic complications—included if measured from the start of surgery, defined a priori and measured equally in both groups. We will use follow-up that is closest to including 7 days after the end of surgery.

- New arterial or deep venous thrombosis

- Pulmonary embolism

Categorical

Relative risk

18. Cost—we will include any cost outcomes from studies where a numerical cost outcome has been clearly defined and equally measured for both groups.

Numerical

Standardised mean difference

  1. We will include data for the following outcomes if they were specifically measured in both groups and defined a priori